


10/14 RECEIVED 0500 #4


<b>CERTIFICATE OF MAILING</b>			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231			
Typed or Printed Name		Donna Macedo	
Signature		Date	
<b>TRANSMITTAL FORM</b> <i>(to be used for all correspondence after initial filing)</i>		TECH CENTER 1600/2900	
		9/13/2000	
		Attorney Docket	THUR-001
		First Named Inventor	Hoffman, et al.
		Application Number	09/582,964
		Filing Date	July 6, 2000
		Group Art Unit	N/A
Examiner Name	N/A		
		Title Use of Serine Protease Inhibitors to Inhibit Pathophysiology and Neuropathology in a Host	



<b>ENCLOSURES (check all that apply)</b>		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Amendment/Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement, International Search Report, 1449 and 12 references <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 (with copy of Notice to File Missing Parts)	<input type="checkbox"/> Issue Fee Transmittal (with copy of PTOL-85B) <input type="checkbox"/> Formal Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition Routing Slip and Accompanying Petition <input type="checkbox"/> To Convert a Provisional Application <input type="checkbox"/> Power of Attorney <input type="checkbox"/> Revocation <input type="checkbox"/> Associate <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement	<input type="checkbox"/> Request for Refund <input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below): Return Postcard _____ _____ _____

<b>SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT</b>			
Individual Name	Bret E. Field	Registration No.	37,620
Firm Name	BOZICEVIC, FIELD & FRANCIS LLP		
Signature			
Date	9.13.00		

<b>CERTIFICATE OF MAILING</b>			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date.			
Typed or Printed Name	Donna Macedo		
Signature	<i>Donna Macedo</i>	Date	9/13/2000
<b>INFORMATION DISCLOSURE STATEMENT</b>  Address to: Commissioner for Patents Washington, D.C. 20231		Attorney Docket	THUR-001
		First Named Inventor	Hoffman, et al.
		Application Number	09/582.964
		Filing Date	July 6, 2000
		Group Art Unit	1614
		Examiner Name	N/A
		Title	Use of Serine Protease Inhibitors to Inhibit Pathophysiology and Neuropathology in a Host



Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. An International Search Report and Form PTO-1449 listing the references accompanies this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815 may be charged therefor.

Respectfully submitted,  
BOZICEVIC, FIELD & FRANCIS LLP

Date: 9.13.00

By: *Bret E. Field*  
Bret E. Field  
Registration No. 37,620

BOZICEVIC, FIELD & FRANCIS LLP  
200 Middlefield Road, Suite 200  
Menlo Park, CA 94025  
Telephone: (650) 327-3400  
Facsimile: (650) 327-3231  
F:\DOCUMENT\THUR\001\IDS - BEFORE 1ST OA.DOC